Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U1111-1338-2016 | Other Identifier | World Health Organization (WHO) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Semaglutide | Adults initiating semaglutide in routine clinical care and assigned to 0.5, 1.0, 1.7 or 2.4 mg at approximately Week 20. Participants are followed from treatment initiation up to 68 weeks using data collected during routine clinical practice. No study-specific interventions, visits, or procedures are performed. Data are derived from secondary use of routinely collected healthcare data. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Semaglutide | Drug | This is a retrospective, non-interventional study; therefore, no intervention was administered as part of the study. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in body weight | Measured as kilogram (kg) | From index date (day 0) to week 68 (day 476) |
| Change in body weight | Measured as percentage (%) | From index date (day 0) to week 68 (day 476) |
| Proportion of individuals achieving a clinically meaningful weight loss | Binary (yes/no): estimated ≥5% reduction from baseline body weight | From index date (day 0) to week 68 (day 476) |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
The study population comprises adults initiating semaglutide in routine clinical practice.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Novo Nordisk | Contact | (+1) 866-867-7178 | clinicaltrials@novonordisk.com |
| Name | Affiliation | Role |
|---|---|---|
| Clinical Transparency (dept. 2834) | Novo Nordisk A/S | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novo Nordisk Investigational Site | Recruiting | Seattle | Washington | 98039 | United States | |
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D050177 | Overweight |
| D009765 | Obesity |
| ID | Term |
|---|---|
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
Not provided
Not provided
| ID | Term |
|---|---|
| C000591245 | semaglutide |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Novo Nordisk Investigational Site |
| Recruiting |
| London |
| United Kingdom |
| D012816 |
| Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |